Coeptis Completes Significant $10 Million Funding Round
Coeptis, Inc. (NASDAQ: COEP) is making noteworthy strides in biotechnology and artificial intelligence (AI) by closing an impressive $10 million in its Series A Preferred financing round. This round comes as an additional influx of $5.7 million into their previous fundraising efforts, showcasing robust investor trust and an exciting vision for the future of technology-driven therapeutics.
Investment Confidence Spotlight
The financing deal was led by CJC Investment Trust, represented by board member Christopher Calise, who decided to increase their commitment. The financing structure allows Series A Preferred investors to convert their investments into the common stock of Coeptis, set at $8.00 per share. Furthermore, they obtained a 15% equity stake in two newly established subsidiaries: SNAP Biosciences Inc. and GEAR Therapeutics Inc., reinforcing a diversified venture strategy.
Innovative Technologies and Operational Expansion
"The successful closure of our second funding round is a game-changer for our growth trajectory," stated Brian Cogley, CFO of Coeptis. With this capital infusion, Coeptis intends to enhance its operations and shareholder value, particularly through its newly launched Technology Division. The acquisition of the NexGenAI Affiliates Network platform is a highlight of this growth, promising innovation in marketing strategies and operational efficiencies essential for a highly regulated industry like biopharmaceuticals.
Utilization of Funds for Corporate Development
The funds raised in this round are earmarked for vital areas, including shoring up the Company’s balance sheet, paying down existing debts, and supporting general corporate activities. Together with the previously secured $4.3 million, this capital will accelerate ongoing initiatives that incorporate advanced AI solutions and automation in research processes, fundamentally enhancing Coeptis' operational framework.
Driving Innovation and Sustainable Growth
CEO Dave Mehalick expressed enthusiasm over the completion of this funding round, emphasizing, "This financing empowers us not only in cell therapy but also drives our innovation agenda in technology and AI." Coeptis aims to maintain a culture of responsible innovation, leveraging diverse growth prospects to build a self-sustaining business model, ultimately paving the way toward long-term success and profitability.
About COEPTIS, Inc.
At its core, Coeptis is committed to the development of innovative cell therapy platforms targeting cancer, autoimmune disorders, and infectious diseases. With a focus on advancing treatment paradigms and enhancing patient outcomes, the Company's portfolio is rich with assets including groundbreaking technologies gained through licensing agreements with Deverra Therapeutics. These include not only an allogeneic cellular immunotherapy platform but also the clinical-stage DVX201 technology, which specializes in natural killer cell therapies.
Moreover, Coeptis is exploring collaborative opportunities with renowned institutions, such as the University of Pittsburgh for its SNAP-CAR universal multi-antigen CAR technology, and fostering joint ventures with researchers at the prestigious Karolinska Institute.
Establishing a Technology Division
Recently, Coeptis has launched a dedicated Technology Division, concentrating on enhancing effectiveness through technological adaptation. This division is equipped with AI-driven marketing software and robotic process automation obtained from NexGenAI Solutions Group. Such innovations are tailored to streamline business practices, effectively driving overall efficiency within the organization.
Commitment to Compliance and Patient Care
Based in Wexford, PA, Coeptis adheres to stringent regulatory frameworks defined by the FDA, with a commitment to maintaining high standards in all operations, especially concerning patient welfare. This commitment to compliance underscores the Company’s mission to deliver safe and effective therapies.
Frequently Asked Questions
What is the total amount Coeptis raised in this funding round?
Coeptis successfully raised a total of $10 million in its Series A Preferred financing round.
Who led the funding round for Coeptis?
The funding round was led by CJC Investment Trust, under the leadership of board member Christopher Calise.
What are the primary uses for the raised funds?
The funds will be used to strengthen the balance sheet, repay debts, and support various corporate purposes, including enhancing operational capabilities.
What innovations is Coeptis focusing on with this funding?
Coeptis is focusing on advancing AI integration and improving its marketing and operational processes through new technologies within its Technology Division.
Where is Coeptis headquartered?
Coeptis is headquartered in Wexford, PA, dedicated to ensuring regulatory compliance and patient care in all its operations.
